Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Efficacy and Safety Study Comparing Concentration-Controlled Everolimus in Two Doses (1.5 and 3.0 mg/Day Starting Doses) With Reduced Cyclosporine Versus 1.44 g Mycophenolic Acid (as Sodium Salt) With Standard Dose Cyclosporine in de Novo Renal Transplant Recipients

Next Previous
X
Search
Trial Profile

Efficacy and Safety Study Comparing Concentration-Controlled Everolimus in Two Doses (1.5 and 3.0 mg/Day Starting Doses) With Reduced Cyclosporine Versus 1.44 g Mycophenolic Acid (as Sodium Salt) With Standard Dose Cyclosporine in de Novo Renal Transplant Recipients

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 03 Nov 2021

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Everolimus (Primary) ; Basiliximab; Ciclosporin; Corticosteroids; Mycophenolate sodium
  • Indications Renal transplant rejection
  • Focus Registrational; Therapeutic Use
  • Sponsors Novartis

    • Most Recent Events

    • 16 Sep 2015 Results from 12 and 24-Month multivariate analysis presented at the 17th Congress of the European Society for Organ Transplantation.
    • 16 Sep 2015 Results of post-hoc analysis presented at the 17th Congress of the European Society for Organ Transplantation
    • 11 Sep 2013 Results comparing tolerability of 2 trials (A2309 and H2304 in in kidney and liver transplant recipients, respectively) presented at the 16th Congress of the European Society for Organ Transplantation.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top